Dementia and COVID-19, a Bidirectional Liaison: Risk Factors, Biomarkers, and Optimal Health Care
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, přehledy
PubMed
34092646
DOI
10.3233/jad-210335
PII: JAD210335
Knihovny.cz E-zdroje
- Klíčová slova
- Alzheimer’s disease, COVID-19, SARS-CoV-2, cognition, dementia,
- MeSH
- Alzheimerova nemoc * patofyziologie psychologie MeSH
- biologické markery analýza MeSH
- COVID-19 komplikace imunologie psychologie terapie MeSH
- kognitivní dysfunkce * imunologie patofyziologie virologie MeSH
- komorbidita MeSH
- lidé MeSH
- mozek * diagnostické zobrazování metabolismus patofyziologie virologie MeSH
- neuroimunomodulace imunologie MeSH
- neurozobrazování metody MeSH
- péče o pacienta MeSH
- postakutní syndrom COVID-19 MeSH
- SARS-CoV-2 MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- biologické markery MeSH
Cognitive impairment following SARS-CoV-2 infection is being increasingly recognized as an acute and possibly also long-term sequela of the disease. Direct viral entry as well as systemic mechanisms such as cytokine storm are thought to contribute to neuroinflammation in these patients. Biomarkers of COVID-19-induced cognitive impairment are currently lacking, but there is some limited evidence that SARS-CoV-2 could preferentially target the frontal lobes, as suggested by behavioral and dysexecutive symptoms, fronto-temporal hypoperfusion on MRI, EEG slowing in frontal regions, and frontal hypometabolism on 18F-FDG-PET. Possible confounders include cognitive impairment due to hypoxia and mechanical ventilation and post-traumatic stress disorder. Conversely, patients already suffering from dementia, as well as their caregivers, have been greatly impacted by the disruption of their care caused by COVID-19. Patients with dementia have experienced worsening of cognitive, behavioral, and psychological symptoms, and the rate of COVID-19-related deaths is disproportionately high among cognitively impaired people. Multiple factors, such as difficulties in remembering and executing safeguarding procedures, age, comorbidities, residing in care homes, and poorer access to hospital standard of care play a role in the increased morbidity and mortality. Non-pharmacological interventions and new technologies have shown a potential for the management of patients with dementia, and for the support of their caregivers.
Clinical Imaging Sciences Centre Brighton and Sussex Medical School Brighton UK
Danish Dementia Research Centre Rigshospitalet University of Copenhagen Copenhagen Denmark
Department of Neurology Osijek University Hospital Center Osijek Croatia
Department of Neuroscience University of Genoa Genoa Italy
Faculty of Medicine University Josip Juraj Strossmayer of Osijek Osijek Croatia
International Clinical Research Center St Anne's University Hospital Brno Brno Czech Republic
Neurology Clinic IRCCS Ospedale Policlinico San Martino Genoa Italy
Non invasive Brain Stimulation Unit IRCCS Fondazione Santa Lucia Rome Italy
Citace poskytuje Crossref.org